新作用靶点的抗糖尿病药物临床研究进展  

Advance in clinical studies of new antidiabetic drugs

作　　者：赵敏[1,2] 杨丽[1] 翟所迪[1] 

机构地区：[1]北京大学第三医院药剂科,北京100191 [2]北京大学药学院,北京100191

出　　处：《中国新药杂志》2010年第3期199-202,共4页Chinese Journal of New Drugs

摘　　要：糖尿病是需要终身治疗的慢性疾病,目前传统的降糖药物均有各自的局限性,如:磺脲类和胰岛素能增加体重,并增加低血糖风险,二甲双胍和α糖苷酶抑制剂有消化道反应,噻唑烷二酮类可引起水肿、体重增加并有可能增加心衰和骨折风险。糖尿病治疗需要新作用靶点的抗糖尿病药物。通过查阅文献对近几年已经上市和正在进行临床研究的新作用靶点的抗糖尿病药物进行分析、归纳和总结。文中就胰高血糖素样肽-1受体激动剂、二基肽酶-4抑制剂、2型钠葡萄糖转运子抑制剂和葡萄糖激酶激动剂分别从药物的作用机制、临床疗效和安全性三方面进行阐述。Diabetes is a chronic disease, and needs lifelong treatment. The traditional antidiabetic drugs have their limitations. Sulfonylureas and insulin can increase body weight and induces hypoglycemia. Metformin and a-glycosidase inhibitors result in gastrointestinal reactions. Thiazolidinediones cause edema and weight gain, and increase the risk of heart failure and fractures. Thus, diabetes needs new antidiabetic drugs. After consulting literature, we summarized the drugs for new targets that have been put into market and during ongoing clinical research. These drugs include glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 antagonist, sodium glucose co-transporter 2 antagonist, and glucokinase activators. The article introduced their mechanisms, clinical efficacy and safety.

关 键 词：降糖药物 GLP-1受体激动剂 DPP4抑制剂 SGLT2抑制剂 葡萄糖激酶激动剂 

分 类 号：R977.15[医药卫生—药品]